(NYSEMKT: OSTX) Os Therapies's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Os Therapies's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast OSTX's revenue for 2026 to be $593,189,954, with the lowest OSTX revenue forecast at $542,162,861, and the highest OSTX revenue forecast at $644,217,047. On average, 1 Wall Street analysts forecast OSTX's revenue for 2027 to be $1,301,190,866, with the lowest OSTX revenue forecast at $1,301,190,866, and the highest OSTX revenue forecast at $1,301,190,866.
In 2028, OSTX is forecast to generate $1,971,559,298 in revenue, with the lowest revenue forecast at $1,971,559,298 and the highest revenue forecast at $1,971,559,298.